Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRYSTAL: Tirabrutinib in Relapsed or Refractory Secondary CNS Lymphoma
jRCT2031220529Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirabrutinib in secondary central nervous system lymphoma (SCNSL) and central nervous system B-cell lymphoma, sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate (centrally assessed). Started Dec 2022; status: active, not recruiting.
02
Drugs
tirabrutinib
03
Conditions
secondary central nervous system lymphoma (SCNSL)central nervous system B-cell lymphoma
Beyond the preview
Go deeper on jRCT2031220529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220529.